Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Melanoma/Skin Cancer
•
Dermatology
Are there certain patient characteristics that drive you to recommend intralesional 5-FU or MTX for a large SCC on the back?
Related Questions
How would you palliate a large, symptomatic vaginal melanoma recurrence with limited small pelvic lymph node metastases?
What are your favorite strategies in fixing post-surgical depressions from facial flaps?
What patient characteristics or clinical scenarios guide the decision in performing slow Mohs procedures?
How would you manage a large area of multiple, recurrent cutaneous squamous cell carcinomas of the scalp with ulcerations and non-healing areas despite cryotherapy, multiple Mohs procedures, and 5-FU?
What biologics would you use in a patient with rheumatoid arthritis who developed multiple basal cell carcinomas requiring Mohs surgery while on a TNF-inhibitor and did not respond to rituximab?
How frequently do you recommend skin cancer screens in your patients with kidney transplants who are on immunosuppression?
What is the recommended approach for systemic therapy in a patient with metastatic cutaneous squamous cell carcinoma with active autoimmune disease (dermatomyositis)?
In what clinical scenarios do you consider pre- or post-treatment with Imiquimod for cutaneous melanoma?
In patients with multiple basal cell carcinoma lesions on vismodegib, would you hold vismodegib while delivering radiation therapy to one locally advanced BCC lesion that was not amenable to surgery?
How do you approach patients with advanced resectable basal cell carcinoma for possible use of hedgehog inhibitors?
